ArticleMagma (New York, N.Y.)2026
Relaxivity comparison of Gadoteric acid and Gadopiclenol using clinical and reference MRI sequences at 1.5 T.
Article in Magma (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGadolinium-based contrast agents (GBCAs) exhibit variable relaxivity, and accurate relaxivity assessment is essential both for technical characterization and for optimizing clinical protocols. While reference relaxometry sequences are considered the gold standard for T1 and T2 quantification, clinical T1/T2 mapping techniques are used in routine MRI despite known limitations. This study aimed to compare relaxivity measurements obtained with reference relaxometry and clinically available T1/T2 mapping sequences at 1.5 T, using Gadoteric acid and Gadopiclenol as test agents.
methodsA phantom containing multiple dilutions of Gadoteric acid (0.1-3.0 mM) and Gadopiclenol (0.05-1.5 mM) was scanned on a routine 1.5 T MRI system. T1 relaxivity was assessed with spin-echo, inversion recovery, and clinical mapping techniques, while T2 relaxivity was measured with multi-echo spin echo and clinical mapping protocols. Relaxivity constants were derived from linear fitting. Water and oil vials were included as reference samples to verify signal stability and fitting consistency.
resultsClinical mapping sequences yielded relaxivity values broadly consistent with reference methods, although their performance varied depending on the T1/T2 range. MP2RAGE showed non-physiological behavior at high gadolinium concentrations (very short T1 values), MOLLI exhibited reduced precision for the shortest T1 values, and the cardiac T2 mapping sequence had to be excluded due to inconsistent measurements in vials with very short T2 values. As expected, Gadopiclenol demonstrated higher r₁ and r₂ relaxivity than Gadoteric acid across all techniques.
conclusionClinical T1/T2 mapping sequences can provide reliable relaxivity estimates over most of the relevant range but show predictable limitations at extreme relaxation times. Reference relaxometry remains the most accurate approach. Using two contrast agents with different relaxivity profiles allowed a robust comparison of the strengths and limitations of clinical versus reference relaxometry techniques. Gadopiclenol exhibited higher relaxivity than Gadoteric acid under phantom conditions, consistent with its potential for dose-efficient protocols, although any clinical dose reduction requires dedicated in vivo validation.
Indexed as
Identifiers
42593609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.